109 related articles for article (PubMed ID: 30825517)
1. Difference in megakaryocyte expression of GATA-1, IL-6, and IL-8 associated with maintenance of platelet counts in patients with plasma cell neoplasm with dysmegakaryopoiesis.
Kim H; Lee MK; Kim HR
Exp Hematol; 2019 May; 73():13-17.e2. PubMed ID: 30825517
[TBL] [Abstract][Full Text] [Related]
2. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
Desterke C; Martinaud C; Guerton B; Pieri L; Bogani C; Clay D; Torossian F; Lataillade JJ; Hasselbach HC; Gisslinger H; Demory JL; Dupriez B; Boucheix C; Rubinstein E; Amsellem S; Vannucchi AM; Le Bousse-Kerdilès MC
Haematologica; 2015 Jun; 100(6):757-67. PubMed ID: 25840601
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
Hsu HC; Lee YM; Tsai WH; Jiang ML; Ho CH; Ho CK; Wang SY
Oncology; 2002; 63(1):64-9. PubMed ID: 12187073
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytopoiesis and apoptosis in patients with myelodysplastic syndromes.
Li X; Pu Q
Leuk Lymphoma; 2005 Mar; 46(3):387-91. PubMed ID: 15621828
[TBL] [Abstract][Full Text] [Related]
5. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocytic differentiation of a leukemic cell line, MC3, by phorbol ester: induction of glycoprotein IIb/IIIa and effects on expression of IL-6, IL-6 receptor, mpl and GATA genes.
Okabe M; Kunieda Y; Shoji M; Nakane S; Kurosawa M; Tanaka J; Hansen SR; Asaka M
Leuk Res; 1995 Dec; 19(12):933-43. PubMed ID: 8632663
[TBL] [Abstract][Full Text] [Related]
7. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.
Huang Z; Richmond TD; Muntean AG; Barber DL; Weiss MJ; Crispino JD
J Clin Invest; 2007 Dec; 117(12):3890-9. PubMed ID: 18060035
[TBL] [Abstract][Full Text] [Related]
8. c-Myb and GATA-1 alternate dominant roles during megakaryocyte differentiation.
García P; Berlanga O; Vegiopoulos A; Vyas P; Frampton J
J Thromb Haemost; 2011 Aug; 9(8):1572-81. PubMed ID: 21668739
[TBL] [Abstract][Full Text] [Related]
9. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes.
Hou M; Andersson PO; Stockelberg D; Mellqvist UH; Ridell B; Wadenvik H
Br J Haematol; 1998 Jun; 101(3):420-4. PubMed ID: 9633881
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Gordon MS; Nemunaitis J; Hoffman R; Paquette RL; Rosenfeld C; Manfreda S; Isaacs R; Nimer SD
Blood; 1995 Jun; 85(11):3066-76. PubMed ID: 7538815
[TBL] [Abstract][Full Text] [Related]
11. Dual role of IL-21 in megakaryopoiesis and platelet homeostasis.
Benbarche S; Strassel C; Angénieux C; Mallo L; Freund M; Gachet C; Lanza F; de la Salle H
Haematologica; 2017 Apr; 102(4):637-646. PubMed ID: 28057742
[TBL] [Abstract][Full Text] [Related]
12. The role of cytokines and transcription factors in megakaryocytopoiesis.
Yang M; Li K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Dec; 10(6):580-5. PubMed ID: 12513728
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietic cytokines and platelet count in multiple myeloma.
Ozkurt ZN; Yağci M; Sucak GT; Kirazli S; Haznedar R
Platelets; 2010; 21(1):33-6. PubMed ID: 19891528
[TBL] [Abstract][Full Text] [Related]
14. Megakaryocyte apoptosis in immune thrombocytopenia.
Vrbensky JR; Nazy I; Toltl LJ; Ross C; Ivetic N; Smith JW; Kelton JG; Arnold DM
Platelets; 2018 Nov; 29(7):729-732. PubMed ID: 29787328
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on bone marrow megakaryocytes in children with thrombocytopenic purpura, aplastic anemia and myelodysplastic syndrome].
Hu T; Shi XD; Feng YL; Liu R; Li JH; Chen J; Wang TY
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):183-7. PubMed ID: 15833188
[TBL] [Abstract][Full Text] [Related]
16. [An immunohistochemical study on megakaryocytes in patients with myelodysplastic syndromes].
Liu SQ; Liu XF; Song SJ
Zhonghua Bing Li Xue Za Zhi; 1994 Oct; 23(5):288-90. PubMed ID: 7874762
[TBL] [Abstract][Full Text] [Related]
17. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
Anoop P; Atra A
J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
[TBL] [Abstract][Full Text] [Related]
18. Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.
Thiele J; Quitmann H; Wagner S; Fischer R
J Clin Pathol; 1991 Apr; 44(4):300-5. PubMed ID: 2030148
[TBL] [Abstract][Full Text] [Related]
19. [Study on pathophysiology of the myelodysplastic syndromes (MDS)--pattern of dysmegakaryopoiesis related to leukemic transformation].
Tomonaga M; Jinnai I; Kuriyama K; Nonaka H; Amenomori T; Matsuo T; Yoshida Y; Sasagawa I; Sadamori N; Ichimaru M
Rinsho Ketsueki; 1989 Oct; 30(10):1788-99. PubMed ID: 2593245
[TBL] [Abstract][Full Text] [Related]
20. Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia.
Goasguen JE; Bennett JM; Bain BJ; Brunning RD; Vallespí MT; Tomonaga M; Zini G; Renault A;
Leuk Res; 2016 Jun; 45():75-81. PubMed ID: 27107657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
